Digital Assistant Supported Medication Adherence and Medical Monitoring Syst

描述(申请人提供)：创新行动有限责任公司，总部设在俄亥俄州阿克伦，计划向市场推出一种基于个人数字助理的健康数据收集和报告系统。对研究药物对老年人的影响感兴趣的研究人员将成为我们产品的初始市场。我们把我们的用药依从性和数据收集系统称为iRxRMinder“系统”。该软件是专门设计的，将为老年人使用进行测试。该软件是专门设计的，将为老年人使用进行测试。该系统将最先进的药物提醒和实时现场数据收集和报告软件整合在一个完全便携的包中。我们将与我们的商业合作伙伴在第二阶段将iRxRminder系统与现有的电子病历系统集成在一起。我们的硬件包括理想的个人数字助理和集成的药丸载体，以确保个人携带该系统。该地堡案已获得实用新型专利(美国专利号7337899)、九项外观设计专利(美国专利号：D501303-D501309、D509055柱体)和一项正在申请的专利。第一阶段将包括开发软件和完成可行性研究。在地区医院接受急性治疗的符合条件的缺血性中风和短暂性脑缺血发作(TIA)患者将获得同意，然后随机分为干预组或对照组。在随机抽样时，对照组患者将接受卒中后教育和医疗信息日记，帮助他们进行出院后自我管理。干预组的患者将收到一个装有iRxRminder软件的个人数字助理，该软件预先编程了他们的药物治疗方案，以及一个带有集成药盒的箱子。患者将在家访中接受使用个人数字助理的所有功能的培训，包括练习对iRxRMinder服药和调查提示的反应。第一阶段的目标是证明老年人对中风后充分使用现有功能的兴趣和能力，并在培训后通过全面掌握测试和60天的使用证明成功使用。在60天结束时，统计测试将被用来确定老年人是否通过稳定使用软件来改善中风后护理的自我管理，这些软件支持1)药物提醒，2)医学和态度调查，以及3)介绍与中风有关的教育材料；与使用以前中风后护理研究中使用的印刷小册子的对照组进行比较。可行性研究将提供必要的实地经验，以确定在第二阶段全面开展的健康结果研究的招聘率、参与率和可行的实地测试数据收集程序。与公共健康相关：与药物有关的问题给美国经济带来了巨大的成本。估计的金额从760亿美元(Johnson&Bootman，1995)到1770亿美元(Ernst And Grizzy2001)不等。缺乏坚持会导致不必要的疾病进展、疾病并发症、功能能力下降、生活质量下降，甚至过早死亡。我们之前的实验室(Sterns和Mayhorn，2006)和扩展的实地研究(Sterns，2005)对44名老年人(M=72岁)进行了研究。将智能手机与附带的药盒结合使用，提供了以下证据：1)提高服药依从性；2)作为专家为患者服药的纽带；3)向医疗专业人员提供反馈，以更好地指导用药方案。这项拟议的研究将证明该系统在第一阶段用于老年人的可行性，并证明在第二阶段为医生和老年患者提供的信息的实用性。随着时间的推移，我们相信该产品可以演变为老年人的认知假体，将降低整体治疗成本，延长独立性，并增强成功的衰老。

DESCRIPTION (provided by applicant): Creative Action LLC, based in Akron, Ohio, plans to bring to market a personal digital assistant-based health data gathering and reporting system. Researchers interested in studying the effects of medications on older adults will be the initial market for our product. We call our medication adherence and data gathering system the iRxReminder" System. The software is specifically designed and will be tested for use by older adults. The software is specifically designed and will be tested for use by older adults. The system brings together state-of- the-art medication reminding and real-time field data collection and reporting software in a completely portable package. With our commercial partners we will integrate the iRxReminder System with existing electronic medical record systems in Phase II. Our hardware includes a desirable personal digital assistant and integrated pill carrier that ensures an individual will carry the system with them. The pillbox case has been awarded a utility patent (US Patent No. 7337899), nine design patents (US Patent No. D501303-D501309, D509055 Pillbox), and one patent pending. Phase I will include development of the software and completion of a feasibility study. Eligible ischemic stroke and transient ischemic attack (TIA) patients undergoing acute treatment at a regional hospital will be approached for consent and then randomized into either the intervention or control group. At the time of randomization, patients in the control group will receive a post-stroke education and medical information diary to assist them in post-discharge self-management. Patients in the intervention group will receive a personal digital assistant with the iRxReminder software preprogrammed with their medication regimen, and a case with the integrated pillbox. Patients will receive training in use of the all the features of the personal digital assistant at a home visit, including practice responding to the iRxReminder medication-taking and survey prompts. The objectives of Phase I are to demonstrate that older adults have an interest in and capacity post-stoke to sufficiently use the features available and to demonstrate successful usage following training, both through a comprehensive mastery test and through 60 days of usage. At the end of 60 days statistical test will be used to determine if older adults utilize the device in improving self-management of care following a stroke through steady use of software that supports 1) medication reminding, 2) medical and attitudinal surveying, and 3) presentation of educational materials related to stroke; compared to a control group using a printed booklet used in a previous post-stroke care study. The feasibility study will provide the field experience necessary to determine recruitment rates, participation rates, and workable field test data collection procedures for a fully powered health outcomes study in Phase II. PUBLIC HEALTH RELEVANCE: Medication-related problems represent a huge cost to the United States economy. Estimates range from $76 billion dollars (Johnson & Bootman, 1995) to $177 billion (Ernst and Grizzle, 2001). Lack of adherence leads to unnecessary disease progression, disease complications, reduced functional abilities, lower quality of life, and even premature death. Our previous lab (Sterns and Mayhorn, 2006) and extended field research (Sterns, 2005) with 44 older adults (M = 72 yrs.) using a Smartphone in combination with an attached pillbox case provided evidence of 1) improving medication adherence; 2) serving as a link between specialists medicating the individual; and 3) providing feedback to healthcare professionals to better direct medication regimens. The proposed research will demonstrate the feasibility of the system for older adults in Phase I, and demonstrate the utility of the information provided for physicians and for older adult patients in Phase II. Over time, we believe the product can evolve to serve as a cognitive prosthesis for older adults that will reduce overall treatment costs and extend independence and enhance successful aging.